COMMUNIQUÉS West-GlobeNewswire

XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

26/09/2019 - 22:07

Includes royalty interest in NIR178 EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the [...]

Otonomy to Present at the Cantor Global Healthcare Conference

26/09/2019 - 22:05

SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D [...]

Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 22:05

REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), [...]

Evelo Biosciences to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 22:05

CAMBRIDGE, Mass,, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that [...]

MyoKardia to Present at 2019 Cantor Global Healthcare Conference

26/09/2019 - 22:05

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at the 2019 Cantor Global [...]

AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019

26/09/2019 - 22:01

Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month XLRP dose expansion data demonstrates [...]

Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019

26/09/2019 - 22:01

DUBLIN, Ireland, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat [...]

Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

26/09/2019 - 22:01

STAMFORD, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by [...]

Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 22:01

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]

Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting

26/09/2019 - 22:00

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from FORTITUDE-ALS ( F unctional O utcomes in a R andomized T rial of I [...]

Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

26/09/2019 - 22:00

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate [...]

European Commission Approves Trogarzo®

26/09/2019 - 20:13

MONTREAL, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo ® (ibalizumab) was approved today by the European Commission. “The approval of [...]

La Commission européenne approuve Trogarzo(MD)

26/09/2019 - 20:13

MONTRÉAL, 26 sept. 2019 (GLOBE NEWSWIRE) -- Theratechnologies inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que Trogarzo MD (ibalizumab) a été approuvée par la Commission européenne. « L’approbation de [...]

Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

26/09/2019 - 19:50

TCT19: First Results from Onyx ONE Global Study Also Show Superior Acute Performance and Build Upon Robust Clinical Evidence for Resolute Onyx with Shortened DAPT DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE [...]

Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019

26/09/2019 - 19:00

This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. Today, September 26, 2019, Oasmia Pharmaceutical AB (publ) held its Annual General Meeting ( [...]

2019 Half-year consolidated results: Deinove’s progress coming to fruition

26/09/2019 - 18:30

2019 Half-year consolidated results: Deinove’s progress coming to fruition Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections Communication by [...]

Résultats semestriels 2019 : Matérialisation des avancements de DEINOVE

26/09/2019 - 18:30

Résultats semestriels 2019 : Matérialisation des avancements de DEINOVE Lancement de l’essai de Phase II testant DNV3837 en traitement de première ligne des infections gastrointestinales sévères à Clostridioides [...]

Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference

26/09/2019 - 18:00

CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel [...]

Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 17:50

DEVON, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]